Peptilogics Raises $78M to Propel Development of Prosthetic Joint Infection Treatment

Peptilogics concludes oversubscribed Series B2 financing round, securing $78 million to advance zaloganan (PLG0206) for prosthetic joint infections.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here